Early-phase trials are critical to the production of pharmaceutical products. With a 40-year history in science, Quotient Bioresearch offers a comprehensive range of services dedicated to excellence in drug discovery and development.
Quotient Bioresearch is dedicated to providing the best service and highest quality data to help clients make the right decisions to further their drug development programmes. The company employs over 350 scientists and clinical research professionals working within purpose-built, state-of-the-art laboratory facilities in Cambridgeshire and Northamptonshire, and a specialist phase 1 clinical unit in Nottingham, UK.
Providing solutions for early phase (discovery through to proof-of-concept clinical trials) and specialist laboratory services, Quotient Bioresearch's unique heritage and combination of capabilities allow an integrated approach to the following areas:
Early clinical development
Quotient Bioresearch's 40-year heritage as a leading sports drug surveillance laboratory in analytical science has enabled the development of a broad, innovative bioanalytical sciences group with the ability to integrate bioanalysis with biomarker and central laboratory capabilities.
The extensive portfolio of mass spectrometry, immunochemistry, clinical laboratory analysers, multiplexing and cell-based assays enables the company to support the analysis of small molecules and biologicals, from discovery to late phase clinical trials.
Quotient Bioresearch is unique in its ability to provide custom radiosynthesis services alongside a full range of DMPK studies to support the development of new chemical entities. As well as non-regulatory and regulatory preclinical in vitro and in vivo studies, it has significant experience in clinical metabolism including microdosing, light label and human AME studies. This breadth of capability enables the company to provide services on an individual study basis or manage entire metabolism programmes.
Quotient Bioresearch provides a wide range of custom chemistry services including API synthesis, labelling of APIs with radio and stable isotopes, and GMP manufacture of APIs (unlabelled or labelled) to kilogramme scale. Furthermore, its chemistry services can be incorporated into integrated preclinical and clinical development programmes.
Quotient Bioresearch has 25 years' experience in all aspects of microbiology required for the discovery and development of antimicrobials. Its ongoing global surveillance activities include an extensive library of clinical isolates with particular capabilities in a typical bacteria and molecular epidemiology.
Pharmaceutical Profiles joined the Quotient Group in December 2008, bringing innovative technologies and expertise to optimise drug delivery and performance within the clinic. With capabilities for GMP manufacturing and GCP clinical trials in the same facility, Quotient Bioresearch developed RapidFACT, a novel formulation development, manufacturing and clinical testing approach.
Combined with innovative imaging, drug delivery technologies such as the Enterion capsule, Quotient Bioresearch helps clients optimise oral, intravenous and inhaled clinical dosage forms. Through ivMicrotracer, Microdosing/phase 0 and tracer metabolism studies, the company offers a sophisticated method of establishing the key drivers of drug bioavailability.
Quotient Bioresearch combines the expertise of established contract research organisations to offer a portfolio of services with specialist capabilities in bioanalysis, microbiology, radiosynthesis, metabolism and early clinical development.